Antibiotic treatment of bacterial vaginosis to prevent preterm delivery: Systematic review and individual participant data meta‐analysis

• Published in: Paediatric and perinatal epidemiology Vol. 37; no. 3; pp. 239 - 251
• Main Authors: Klebanoff, Mark A., Schuit, Ewoud, Lamont, Ronald F., Larsson, Per‐Göran, Odendaal, Hein J., Ugwumadu, Austin, Kiss, Herbert, Petricevic, Ljubomir, Andrews, William W., Hoffman, Matthew K., Shennan, Andrew, Seed, Paul T., Goldenberg, Robert L., Emel, Lynda M., Bhandaru, Vinay, Weiner, Steven, Larsen, Michael D.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2023
• Subjects: Anti-Bacterial Agents - therapeutic use; Antibiotics; Bacteria; bacterial vaginosis; Clindamycin; Clindamycin - therapeutic use; Clinical trials; Female; Gestation; Heterogeneity; Humans; individual participant data; Infant, Newborn; Meta-analysis; Metronidazole; Metronidazole - therapeutic use; Pregnancy; Premature Birth - epidemiology; Premature Birth - prevention & control; preterm delivery; Searching; Sensitivity analysis; Subgroups; Systematic review; Vaginosis; Vaginosis, Bacterial - drug therapy; Vaginosis, Bacterial - prevention & control; individual participant data; bacterial vaginosis; meta-analysis; metronidazole; clindamycin; systematic review; preterm delivery
• ISSN: 0269-5022; 1365-3016; 1365-3016
• DOI: 10.1111/ppe.12947

Background Bacterial vaginosis (BV) increases preterm delivery (PTD) risk, but treatment trials showed mixed results in preventing PTD. Objectives Determine, using individual participant data (IPD), whether BV treatment during pregnancy reduced PTD or prolonged time‐to‐delivery. Data Sources Cochrane Systematic Review (2013), MEDLINE, EMBASE, journal searches, and searches (January 2013–September 2022) (“bacterial vaginosis AND pregnancy”) of (i) clinicaltrials.gov; (ii) Cochrane Central Register of Controlled Trials; (iii) World Health Organization International Clinical Trials Registry Platform Portal; and (iv) Web of Science (“bacterial vaginosis”). Study Selection and Data Extraction Studies randomising asymptomatic pregnant individuals with BV to antibiotics or control, measuring delivery gestation. Extraction was from original data files. Bias risk was assessed using the Cochrane tool. Analysis used “one‐step” logistic and Cox random effect models, adjusting gestation at randomisation and PTD history; heterogeneity by I2. Subgroup analysis tested interactions with treatment. In sensitivity analyses, studies not providing IPD were incorporated by “multiple random‐donor hot‐deck” imputation, using IPD studies as donors. Results There were 121 references (96 studies) with 23 eligible trials (11,979 participants); 13 studies (6915 participants) provided IPD; 12 (6115) were incorporated. Results from 9 (4887 participants) not providing IPD were imputed. Odds ratios for PTD for metronidazole and clindamycin versus placebo were 1.00 (95% CI 0.84, 1.17), I2 = 62%, and 0.59 (95% CI 0.42, 0.82), I2 = 0 before; and 0.95 (95% CI 0.81, 1.11), I2 = 59%, and 0.90 (95% CI: 0.72, 1.12), I2 = 0, after imputation. Time‐to‐delivery did not differ from null with either treatment. Including imputed IPD, there was no evidence that either drug was more effective when administered earlier, or among those with a PTD history. Conclusions Clindamycin, but not metronidazole, was beneficial in studies providing IPD, but after imputing data from missing IPD studies, treatment of BV during pregnancy did not reduce PTD, nor prolong pregnancy, in any subgroup or when started earlier in gestation.